With an aging baby boomer population, the medical device and biotechnology industry is going strong. More Americans need drugs and treatments as they age, and that produces big profit opportunities for companies with the next great health care product.
Santarus is a biotech stock that has an exceptional ability when it comes to sales and marketing in niche specialty markets, and is an attractive partner to smaller companies that are on their way up.
Currently, the company’s products include gastrointestinal reflux treatment drug Zegerid, as well as anti-diabetes drugs Glumetza and Cycloset.
However, the story here is the company’s products under development that will reach the market in the next few years — including Budesonide MMX, a treatment for ulcerative colitis, Rhucin, treatment for hereditary angioedema, and Rifamycin SV MMX, a drug for travelers’ diarrhea. This is a promising pipeline for the company, and management believes that these drugs have a combined peak sales potential of $650 million.
As a development stage company, Santarus just made the transition from posting losses to instead posting 34.7% annual sales growth and 102.3% earnings growth.
For its upcoming quarter, the analyst community is anticipating 59.2% sales growth and 188.9% earnings growth.